AU6868000A - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
AU6868000A
AU6868000A AU68680/00A AU6868000A AU6868000A AU 6868000 A AU6868000 A AU 6868000A AU 68680/00 A AU68680/00 A AU 68680/00A AU 6868000 A AU6868000 A AU 6868000A AU 6868000 A AU6868000 A AU 6868000A
Authority
AU
Australia
Prior art keywords
group
hydrogen atom
lower alkyl
formula
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU68680/00A
Other languages
English (en)
Inventor
Katsuichi Sudo
Yasuo Sugiyama
Yasuhiko Wada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU6868000A publication Critical patent/AU6868000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU68680/00A 1999-09-03 2000-09-01 Pharmaceutical composition Abandoned AU6868000A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP25044399 1999-09-03
JP11/250443 1999-09-03
JP2000/56021 2000-02-28
JP2000056021 2000-02-28
PCT/JP2000/005951 WO2001017513A2 (en) 1999-09-03 2000-09-01 Pharmaceutical composition comprising an insulin sensitizer

Publications (1)

Publication Number Publication Date
AU6868000A true AU6868000A (en) 2001-04-10

Family

ID=26539777

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68680/00A Abandoned AU6868000A (en) 1999-09-03 2000-09-01 Pharmaceutical composition

Country Status (14)

Country Link
EP (1) EP1212090A2 (zh)
KR (1) KR20020063555A (zh)
CN (1) CN1372476A (zh)
AR (1) AR031674A1 (zh)
AU (1) AU6868000A (zh)
CA (1) CA2383946A1 (zh)
CO (1) CO5180632A1 (zh)
HK (1) HK1044711A1 (zh)
HU (1) HUP0203285A3 (zh)
NO (1) NO20021036L (zh)
PE (1) PE20010580A1 (zh)
PL (1) PL354295A1 (zh)
RU (1) RU2002108346A (zh)
WO (1) WO2001017513A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051441A1 (fr) 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
CA2443325C (en) 2001-04-04 2011-06-14 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
AU2003242245A1 (en) 2002-06-12 2003-12-31 Sumitomo Pharmaceuticals Co., Ltd. Indole, indazole, and benzazole derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501722A (ja) * 1988-11-14 1992-03-26 ジ・アップジョン・カンパニー 抗―糖尿病、抗―肥満症および抗―アテローム性動脈硬化症薬として有用なα―アミノ―インドール―３―酢酸
WO1991012003A1 (en) * 1990-02-09 1991-08-22 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
ES2159648T3 (es) * 1994-11-29 2001-10-16 Dainippon Pharmaceutical Co Derivado de indol.

Also Published As

Publication number Publication date
WO2001017513A2 (en) 2001-03-15
CO5180632A1 (es) 2002-07-30
KR20020063555A (ko) 2002-08-03
EP1212090A2 (en) 2002-06-12
CA2383946A1 (en) 2001-03-15
NO20021036L (no) 2002-04-26
PE20010580A1 (es) 2001-05-25
WO2001017513A3 (en) 2001-09-20
AR031674A1 (es) 2003-10-01
HUP0203285A2 (hu) 2003-01-28
RU2002108346A (ru) 2003-11-20
NO20021036D0 (no) 2002-03-01
HUP0203285A3 (en) 2003-02-28
PL354295A1 (en) 2004-01-12
CN1372476A (zh) 2002-10-02
HK1044711A1 (zh) 2002-11-01

Similar Documents

Publication Publication Date Title
CA2369694C (en) Agent for improving ketosis
AU754740B2 (en) Pharmaceutical composition for the treatment of diabetes
JP3973280B2 (ja) 医薬
US20030134884A1 (en) Neovascularization inhibitors
US20030060488A1 (en) Drug comprising combination
AU6868000A (en) Pharmaceutical composition
CA2445322C (en) Use of the abc expression promoting agent pioglitazone for the treatment of arteriosclerosis obliterans
JP2001316292A (ja) 医 薬
JP2000080047A (ja) 医 薬
ZA200201151B (en) Pharmaceutical composition.
JP2001294537A (ja) 併用医薬
JP2000355550A (ja) ケトーシス改善剤
AU741226B2 (en) Pharmaceutical composition
JP2001342135A (ja) 血管新生阻害剤
MXPA00010582A (en) Pharmaceutical composition for the treatment of diabetes
JP2003012551A (ja) Ａｂｃ発現促進剤

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20020417